Anti-IDH1 (Hu) from Rat (W09)

Catalogue Number: DIA-W09-DIA

Manufacturer:Dianova
Preservative:0.05% Sodium azide
Physical state:Lyophilized
Type:Monoclonal Primary Antibody - Unconjugated
Alias:IDH1;Isocitrate dehydrogenase [NADP] (cytoplasmic);PICD;IDP;Oxalosuccinate decarboxylase;NADP(+)-specific ICDH;Cytosolic NADP-isocitrate dehydrogenase;Isocitrate Dehydrogenase 1, Soluble
Shipping Condition:RT
Storage Condition:2-8°C
Unit(s): 0.5 ml
Host name: Rat
Clone: W09
Isotype: IgG2a
Immunogen: Peptide sequence 4-120 of human IDH1
Application: ICC, IHC-P, WB, IHC

Description

Description: Isocitrate dehydrogenase (IDH) is an important enzyme in the citric acid cycle and catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate and CO2 while converting NAD+ to NADH. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. Mouse antibody clone H09 (product number #DIA-H09) reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sec-tions from formalin-fixed brain tumor specimens. Therefore this antibody is highly useful for tumor classification. Rat antibody clone W09 detects both wild type (wt) and point mutated IDH1 in glioblastoma (anti-pan-IDH1) and serves as control for the IDH1 point mutation specific mouse antibody clone H09. Moreover, Tan et al. (Mol Cell Proteomics, 2011) have identified IDH1 as a potential diagnostic and prognostic biomarker for Non-small-cell Lung Cancer (NSCLC). These findings suggest that anti-IDH1wt antibody could be used as a histochemical biomarker for prognosis prediction of NSCLC. Human IDH1, wild type & point mutation

Additional Text

Gene Name

IDH1

Purification

Protein A/G Purified

Uniprot ID

O75874

Gene ID

3417

Antibody Clonality

Monoclonal